Table of Contents
- Clinical trial overview
- Who the studies include
- How the trials are designed
- What the trials measure
- Trial-by-trial summary
- Patient-friendly terms
Clinical trial overview
The available studies are investigating Vx-670 in people with myotonic dystrophy type I (DM1), which is the condition named in the trial records.[1][2] Both studies are interventional, meaning researchers give the study treatment and then measure what happens.[1][2] The two trials are both listed as Authorised.[1][2]
Who the studies include
The trial data show that the studies are focused on adult subjects with DM1.[2] One trial is described as long-term safety and efficacy research in patients with DM1, while the other is a phase 1/2 study in adult subjects with DM1.[1][2] Based on the source data, the target population is people living with this specific muscle disease, not the general public.[1][2]
How the trials are designed
One study is a Phase 1 trial with 39 enrolled participants.[1] The other is a Phase 1/2 trial with 44 enrolled participants.[2] These are early-stage studies, which usually help researchers learn about safety first and then look for early signs of benefit.[1][2]
The phase 1/2 study has two parts.[2] Part A evaluates single ascending doses, which means one dose is given and then the dose level is increased in later groups if the study allows it.[2] Part B evaluates single and multiple ascending doses, which means researchers study both one-time dosing and repeated dosing at increasing levels.[2]
Both studies use intravenous administration, meaning the treatment is given through a vein.[1][2] In the phase 1/2 trial, a comparison treatment of 0.9% saline solution is also listed.[2]
What the trials measure
The main goal in both trials is to assess safety and tolerability of Vx-670.[1][2] Safety means whether the treatment causes medical problems, and tolerability means how well people can take it without major difficulty.
In the phase 1 study, safety and tolerability are checked using adverse events, vital signs, electrocardiograms (ECGs), and clinical laboratory values.[1] In the phase 1/2 study, the same safety focus is used, and the measures include adverse events, laboratory test results, standard 12-lead ECGs, vital signs, and the Columbia Suicide Severity Rating Scale (C-SSRS).[2]
The brief summary of the phase 1/2 trial says it also aims to evaluate safety and tolerability in both single and multiple ascending dose settings, which helps researchers learn how people respond across different exposure patterns.[2] The long-term study is specifically described as evaluating long-term safety and tolerability in subjects with DM1.[1]
Trial-by-trial summary
- 2024-517983-47-00: A phase 1 study in 39 people with DM1, focused on long-term safety and tolerability of Vx-670.[1]
- 2023-506028-10-00: A phase 1/2 study in 44 adult subjects with DM1, studying single and multiple ascending doses and safety outcomes.[2]
Patient-friendly terms
Adverse events are unwanted health problems that happen during a study, whether or not the treatment caused them.[1][2] ECG is a heart test that records electrical activity and helps researchers watch for heart changes.[1][2] Laboratory values are results from blood or other lab tests that help show how the body is doing.[1][2]
Vital signs are basic body checks such as blood pressure, pulse, temperature, and breathing rate.[1][2] Tolerability means how well a person can handle the study treatment without major problems.[1][2] Long-term means the study follows people over a longer period to look for effects that may not show up right away.[1]
